Plexāā Secures $4.5 Million to Launch BLOOM⁴³ in the U.S.

Plexāā, a MedTech startup, has successfully closed a $4.5 million funding extension to support the U.S. launch of its BLOOM⁴³ device, designed to reduce complications in breast surgeries. The device utilizes Supraphysiological Preconditioning to improve surgical outcomes, with clinical trials showing promising results in reducing wound healing complications. This funding round, led by TCP Health Ventures and including investments from Thena Capital and over $1.6 million in i4i grant funding from the National Institute for Health and Care Research, positions Plexāā for its upcoming Series A fundraising and market expansion.

The BLOOM⁴³ device, along with its companion app, aims to enhance the patient experience and surgical readiness by leveraging holistic Prehabilitation and preconditioning. Plexāā's founder and CEO, Dr. Saahil Mehta, expressed gratitude towards the team and investors, highlighting the validation of their technology and the potential to impact a wider patient population. The company's collaboration with clinicians and partners worldwide underscores its commitment to making preconditioning a standard of care in surgery.

Investors like Tatum Getty of THENA Capital have praised Plexāā's innovative approach to addressing post-operative complications, emphasizing the device's potential to improve outcomes in women's health and beyond. With plans to expand into additional surgical specialties, Plexāā is at the forefront of transforming surgical care through technology and research.